News
  • Tumor Microenvironment Responsive Shape-Reversal Self-Targeting Virus-Inspired Nanodrug for Imaging-Guided Near-Infrared-II Photothermal Chemotherapy
    Tumor Microenvironment Responsive Shape-Reversal Self-Targeting Virus-Inspired Nanodrug for Imaging-Guided Near-Infrared-II Photothermal Chemotherapy November 6,2023.
    ACS Nano. 2019 Nov 26;13(11):12912-12928. doi: 10.1021/acsnano.9b05425. Epub 2019 Oct 29. Tumor Microenvironment Responsive Shape-Reversal Self-Targeting Virus-Inspired Nanodrug for Imaging-Guided Near-Infrared-II Photothermal Chemotherapy Yang Li 1 2 3, Jinyan Lin 2, Peiyuan Wang 1 2 3, Qiang Luo 1 2 3, Huirong Lin 4, Yun Zhang 1 3, Zhenqing Hou 5, Jingfeng Liu 1 2 3, Xiaolong Liu 1 2 3 Abstract Tumor microenvironment responsive multimodal synergistic theranostic strategies can significantly improve the therapeutic efficacy while avoiding severe side effects. Inspired by the fact that special morphology could enhance photothermal conversion efficiency (PCE) and cellular delivery, we developed an acidic tumor microenvironment responsive shape-reversal metal-organic virus-inspired nanodrug for enhancing near-infrared (NIR)-II PCE, increasing cell adhesion, and activating tumor targeting. First, a NIR-I fluorescence probe (IR825), a chemo-drug (pemetrexed, PEM), and a rare-earth metal ion (Nd(III)) were chosen to synthesize a virus-like nanodrug via coordination-driven assembly. Then, the spike-like surface of the nanodrug was further camouflaged by an acidity-sensitive poly(ethylene glycol) "shell" to create virus-core and sphere-shell hierarchical nanoassemblies, which could efficiently prevent immune clearance and prolong systemic circulation. Interestingly, the acidic tumor microenvironment could trigger the shell detachment of nanoassemblies for shape reversal to produce a virus-like surface followed by re-exposure of PEM to synergistically amplify the cellular internalization while enhancing NIR-II PCE. By utilizing the shell-detached virus-like nanodrug core, the tumor microenvironment specific enhanced NIR-II photothermal chemotherapy can be realized under the precise guidance of fluorescence/photoacoustic imaging, thereby achieving complete tumor elimination without recurrence in a single treatment cycle. We envision that integrating the tumor microenvironment responsive ability with "sphere-to-virus" shape reversal will provide a promising strategy for biomimetic targeted cancer therapy. Keywords: NIR-II photothermal therapy; chemotherapy; shape reversal; tumor microenvironment response; virus-inspired nanodrug. Related products Abbreviation: mPEG-OH Name: Methoxypoly(ethylene glycol) For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com
    View More
  • Tumor Microenvironment Cascade-Responsive Nanodrug with Self-Targeting Activation and ROS Regeneration for Synergistic Oxidation-Chemotherapy
    Tumor Microenvironment Cascade-Responsive Nanodrug with Self-Targeting Activation and ROS Regeneration for Synergistic Oxidation-Chemotherapy November 2,2023.
    Nanomicro Lett. 2020 Sep 14;12(1):182. doi: 10.1007/s40820-020-00492-4. Tumor Microenvironment Cascade-Responsive Nanodrug with Self-Targeting Activation and ROS Regeneration for Synergistic Oxidation-Chemotherapy Yang Li # 1 2 3, Jinyan Lin # 2, Peiyuan Wang 1 2 3, Qiang Luo 1 2 3, Fukai Zhu 4, Yun Zhang 1 3, Zhenqing Hou 4, Xiaolong Liu 5 6 7, Jingfeng Liu 8 9 10 Abstract Carrier-free nanodrug with exceptionally high drug payload has attracted increasing attentions. Herein, we construct a pH/ROS cascade-responsive nanodrug which could achieve tumor acidity-triggered targeting activation followed by circularly amplified ROS-triggered drug release via positive-feedback loop. The di-selenide-bridged prodrug synthesized from vitamin E succinate and methotrexate (MTX) self-assembles into nanoparticles (VSeM); decorating acidity-cleavable PEG onto VSeM surface temporarily shields the targeting ability of MTX to evade immune clearance and consequently elongate circulation time. Upon reaching tumor sites, acidity-triggered detachment of PEG results in targeting recovery to enhance tumor cell uptake. Afterward, the VSeM could be dissociated in response to intracellular ROS to trigger VES/MTX release; then the released VES could produce extra ROS to accelerate the collapse of VSeM. Finally, the excessive ROS produced from VES could synergize with the released MTX to efficiently suppress tumor growth via orchestrated oxidation-chemotherapy. Our study provides a novel strategy to engineer cascade-responsive nanodrug for synergistic cancer treatment. Keywords: Circular amplification of ROS; Positive-feedback loop; Synergistic oxidation-chemotherapy; Targeting activation; Vitamin E nanodrug. Related products Abbreviation: mPEG-OH Name: Methoxypoly(ethylene glycol) For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com
    View More
  • PEGylation of cytochrome c at the level of lysine residues mediated by a microbial transglutaminase
    PEGylation of cytochrome c at the level of lysine residues mediated by a microbial transglutaminase October 30,2023.
    Biotechnol Lett. 2016 Jul;38(7):1121-9. doi: 10.1007/s10529-016-2083-6. Epub 2016 Mar 29. PEGylation of cytochrome c at the level of lysine residues mediated by a microbial transglutaminase Jian Qin Zhou 1, Ting He 1, Jian Wen Wang 2 Abstract Objectives: To establish a method for microbial transglutaminase (mTG)-mediated PEGylation of proteins at the level of lysine (Lys) residues. Results: Carboxybenzyl-glutaminyl-glycinyl-methoxypolyethylene glycol (CBZ-QG-mPEG) was prepared by introducing carboxybenzyl-glutaminyl-glycine (CBZ-QG) to mPEG amine. The analysis by Fourier transform infrared spectroscopy and SDS-PAGE showed that CBZ-QG-mPEG was successfully synthesized and can be recognized by mTG as an acyl donor to modify therapeutic protein, cytochrome c (cyt c). Finally, under an optimized condition (cyt c 0.5 mg/ml, CBZ-QG-mPEG 11.25 mg/ml, mTG 0.5 mg/ml, 37 °C, 2 h), the PEGylation yield reached 76.5 %. Conclusions: This is the first study regarding the PEGylation of protein at the level of Lys residues catalyzed by mTG. The novel method could be employed to immobilize active proteins and modify therapeutic proteins. Keywords: Lysine residue; Microbial transglutaminase; PEGylation; Therapeutic protein; Transglutaminase. Related products Abbreviation: mPEG-NH2 Name: Methoxypoly(ethylene glycol) amine Abbreviation: mPEG-SPA Name: Methoxypoly(ethylene glycol) succinimidyl propionate For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com
    View More
  • Join Us at CPHI Barcelona 2023 – Booth 7D10!
    Join Us at CPHI Barcelona 2023 – Booth 7D10! October 11,2023.
    Dear colleagues and industry partners, We are thrilled to extend a warm invitation to all of you to join us at CPHI Barcelona 2023, one of the most prestigious events in the pharmaceutical and healthcare industry. Our company is proud to be a part of this incredible event, and we're excited to welcome you to our booth, 7D10. Event Details: Date: 24 Oct, 2023–26 Oct, 2023 Location: Fira Barcelona Gran Via Booth: 7D10 At our booth, you'll have the opportunity to connect with our team, explore our latest products and innovations, and engage in meaningful discussions about the future of the pharmaceutical industry. CPHI Barcelona is a hub for networking and knowledge-sharing, and we look forward to exchanging insights with you. Why Visit Booth 7D10? Discover our cutting-edge pharmaceutical solutions. Learn about our commitment to quality and innovation. Meet our team of experts ready to answer your questions. Explore potential collaborations and partnerships. To make the most of your visit, please schedule an appointment with us in advance by contactingsales@sinopeg.com. We believe that collaboration is key to driving the industry forward, and CPHI Barcelona provides the perfect platform for such collaboration.     We can't wait to see you there and discuss how we can work together to achieve excellence in the world of pharmaceuticals. Save the date, visit Booth 7D10, and let's shape the future of healthcare together!
    View More
  • Site-specific PEGylation of Human Growth Hormone by Mutated Sortase A
    Site-specific PEGylation of Human Growth Hormone by Mutated Sortase A September 20,2023.
    Published: 16 May 2018;   DOI:10.1007/s40242-018-8023-3 Chemical Research in Chinese Universities volume 34, pages428–433 (2018) Site-specific PEGylation of Human Growth Hormone by Mutated Sortase A Hui Shi, Qingyang Shi, James T. Oswald, Ying Gao, Leijiao Li & Yunhui Li Abstract Human growth hormone(hGH), a classic therapeutic protein, which promotes growth and wound healing, is released from the pituitary gland.   As a protein drug, its short half-life is its main barrier to therapeutic efficacy.   Various strategies have been designed to prolong its serum half-life, the most common of which is the conjugation with polyethylene glycol(PEG), as this has been shown to significantly extend protein’s serum half-life.   However, PEGylation often results in random conjugation, which can lead to impaired protein function and hinder purification, characterization and evaluation of the PEGylated protein.   Therefore, site specific PEGylation is a promising direction for PEG-protein conjugation.   Here we took advantages of the mutated sortase A(7M) enzyme, which can enzymatically ligate the universal α-amino acids to a C-terminal tagged protein.   This then allows specific modification of the C-terminal of hGH with PEG.   This site-specific bound PEG-hGH has similar efficacy, receptor binding and cell proliferation as wild-type hGH;   however, pharmacokinetic analysis demonstrates that its serum half-life is almost 24 times that of wild-type hGH.   Herein, we provided a promising advancement in the development of site specific PEGylated therapeutic proteins. Related products Abbreviation: mPEG-NH2 Name: Methoxypoly(ethylene glycol) amine For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com
    View More
  • RhB-encapsulating silica nanoparticles modified with PEG impact the vascular endothelial function in endothelial cells and zebrafish model
    RhB-encapsulating silica nanoparticles modified with PEG impact the vascular endothelial function in endothelial cells and zebrafish model September 4,2023.
    Sci Total Environ. 2020 Apr 1;711:134493.   doi: 10.1016/j.scitotenv.2019.134493.   Epub 2019 Oct 4. RhB-encapsulating silica nanoparticles modified with PEG impact the vascular endothelial function in endothelial cells and zebrafish model Shuang Liang 1, Yueyue Chen 1, Shiming Zhang 2, Yuanyuan Cao 1, Junchao Duan 3, Yapei Wang 4, Zhiwei Sun 5 Abstract Silica nanoparticles (SiNPs) have been widely used in human health related products, such as food additives, cosmetics and even drug delivery, gene therapy or bioimaging.   Recently, a first-in-human clinical trial based on polyethylene glycol (PEG)-modified SiNPs had been approved by US FDA to trace melanoma.   However, as a nano-based drug delivery system, its biocompatibility and vascular toxicity are still largely unknown.   Thus, we synthesized the fluorescent SiNPs to explore the biocompatibility and vascular endothelial function, and compare different biological effects caused by PEG-modified and unmodified SiNPs in cells and zebrafish model.   The characterizations of SiNPs and PEG-modified SiNPs were analyzed by TEM, SEM, AFM and DLS, which exhibited relatively good stable and dispersive.   Compared with SiNPs, PEG-modified SiNPs had markedly reduced the inflammatory response and vascular damage in Tg (fli-1: EGFP) and Tg (mpo: GFP) transgenic zebrafish lines, respectively.   Consistent with the in vivo results, the PEG-modified SiNPs had been found to significantly decline the levels of ROS, inflammatory cytokines and mitochondrial-mediated apoptosis in vascular endothelial cells compared to SiNPs, and the ROS scavenger NAC could effectively alleviate the above adverse effects induced by nanoparticles.   Our results suggested that the PEG-modified SiNPs could become more safety via increasing the biocompatibility and decreasing cellular toxicities in living organisms. Keywords: Endothelial cells;   PEG modification;   RhB-encapsulating SiNPs;   Vascular function;   Zebrafish. Related products Abbreviation: mPEG-NH2 Name: Methoxypoly(ethylene glycol) amine For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com
    View More
  • Reactive oxygen species-responsive nanoprodrug with quinone methides-mediated GSH depletion for improved chlorambucil breast cancers therapy
    Reactive oxygen species-responsive nanoprodrug with quinone methides-mediated GSH depletion for improved chlorambucil breast cancers therapy August 14,2023.
    J Control Release. 2018 Mar 28;274:56-68. doi: 10.1016/j.jconrel.2018.01.034. Epub 2018 Feb 2. Reactive oxygen species-responsive nanoprodrug with quinone methides-mediated GSH depletion for improved chlorambucil breast cancers therapy Cheng-Qiong Luo 1, Yu-Xin Zhou 2, Tian-Jiao Zhou 3, Lei Xing 1, Peng-Fei Cui 3, Minjie Sun 3, Liang Jin 4, Na Lu 5, Hu-Lin Jiang 6 Abstract Prodrug-based stimuli-responsive vectors have emerged as highly promising platform. Inspired by the fact that antioxidant systems including glutathione (GSH) make cancer cells adapt to oxidative stress and play a role in the inactivation of alkylating agents like chlorambucil (CHL) inside tumor cells, while arylboronic acid could transform into GSH depleting agent quinone methide (QM) upon degradation by reactive oxygen species (ROS) over-expressed in tumor cells, a ROS-responsive nanoprodrug (denoted by PPAHC) of CHL was established by integrating CHL into diols-containing hydrophilic polymer with self-immolative linker 4-(hydroxymethyl)phenylboronic acid (HPBA). The prodrug could form core-shell nanoparticle and possess high stability during storage. Drug release profile of PPAHC nanoprodrug demonstrated that nature CHL could be quickly released from PPAHC nanoprodrug in the presence of hydrogen peroxide (H2O2). Moreover, PPAHC nanoprodrug showed improved therapeutic efficiency compared to CHL via anti-proliferative study and cell apoptosis assay. Further measurement of GSH content and ROS levels in tumor cells suggested that the synergistic impact resulted from QM-mediated GSH reduction and CHL-induced further oxidative stress insults to tumor cells. In vivo tumor suppression effect and biocompatibility indicated the superiorities of PPAHC nanoprodrug. Accordingly, PPAHC provides a new approach as a ROS-responsive CHL delivery system and has a great potential for cancer therapy. Keywords: Chlorambucil; Glutathione; Nanoprodrug; Quinone methide; Reactive oxygen species; Self-immolative linker. Related products Abbreviation: mPEG-NH2 Name: Methoxypoly(ethylene glycol) amine For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com
    View More
  • Preparation and In Vitro Evaluation of a Multifunctional Iron Silicate@Liposome Nanohybrid for pH-Sensitive Doxorubicin Delivery and Photoacoustic Imaging
    Preparation and In Vitro Evaluation of a Multifunctional Iron Silicate@Liposome Nanohybrid for pH-Sensitive Doxorubicin Delivery and Photoacoustic Imaging July 20,2023.
    Journal of Nanomaterials | Volume 2015 | Article ID 541763 | https://doi.org/10.1155/2015/541763 Preparation and In Vitro Evaluation of a Multifunctional Iron Silicate@Liposome Nanohybrid for pH-Sensitive Doxorubicin Delivery and Photoacoustic Imaging Zehua Liu, Shaoheng Tang, Zhiran Xu, Yingjun Wang, Xuan Zhu, Liang-cheng Li, Wanjin Hong, and Xiumin Wang Abstract For preventing premature drug release in neutral environment and avoiding them being trapped into the endosomal/lysosomal system, we developed a novel iron silicate@liposome hybrid (ILH) formulation, which can be used as a carrier to transport doxorubicin (DOX) in a pH-sensitive manner and to escape from endosomal/lysosomal trapping through “proton-sponge” effect.   The high intensity of photoacoustic signal from in vitro photoacoustic imaging (PAI) experiments suggests that it is a promising candidate for PAI agent, providing the potential for simultaneously bioimaging and cancer-targeting drug delivery.   Cytotoxicity of our formulation toward tumor cells was remarkably higher than free DOX (48.4±7.7% and 26.2±8.4%, P < 0.001).   Confocal laser scanning microscopy experiments showed the enhanced transportation and enrichment process of DOX in QSG-7703 cells.   Taking together, we developed an easy approach to construct a multifunctional anticancer drug delivery/imaging system with a potency as a PAI agent.   The strategy of combining drug carrier and imaging agent is an emerging platform for further construction of nanoparticle and may play a significant role in cancer therapy and diagnosis. Related products Abbreviation: mPEG-NH2 Name: Methoxypoly(ethylene glycol) amine For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com
    View More
first page 1 2 3 4 5 6 7 8 9 10 last page

A total of 20 pages

Copyright © XIAMEN SINOPEG BIOTECH CO., LTD. All Rights Reserved.

Home

Products

News

contact